How price transparency helped an Arizona health system achieve financial turnaround

Healthcare Finance | February 25, 2019

Efforts to understand costs and openly share information on healthcare prices played a key role in a major Arizona health system's successful turnaround from a financial crisis, according to a feature article in the spring issue of Frontiers of Health Services Management, an official publication of the American College of Healthcare Executives. At Maricopa Integrated Health System, price transparency and the demonstration of cost-effective, high-quality service to patients have become strategic imperatives, and essential components of the system's comeback story. In 2014, MIHS was on an "unsustainable financial trajectory," with an operating deficit of more than $74 million. Arizona's largest public healthcare system and a major training center, MIHS is a safety-net system, predominantly serving patients on Medicaid and other public insurance.

Spotlight

Compensation from a Provider to a physician in the form of
items or services (reward, award, or other gratuity) that does
not exceed the annually adjusted cap amount (see below).
Requirements include: The compensation is not determined in a manner that takes into account the volume or value of referrals or other business generated by the referring physician.


Other News
FUTURE OF HEALTHCARE

Laborie Medical Technologies Acquires GI Supply

Laborie Medical Technologies | April 21, 2022

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. announced that it has completed the acquisition of GI Supply, a leader in specialty endoscopy and paracentesis products for gastroenterologists, colorectal surgeons, and interventional radiologists. As part of the transaction, GI Supply and all its employees will be fully integrated into the Laborie business. "We've had the opportunity to work closely with the GI Supply team for two years and are delighted to welcome them into the Laborie family," said Michael Frazzette, President & CEO of Laborie Medical Technologies. "We look forward to working together in our mission to deliver innovative technologies that help preserve and restore human dignity. Gastroenterology will continue to be a core segment for Laborie and legacy GI Supply will lead our effort." In 2020, Laborie and Signet Healthcare Partners, a healthcare growth equity firm, signed an agreement to acquire GI Supply. The combined GI Supply and Laborie product portfolio and commercial capabilities enabled the organizations to reach a larger customer base and offer healthcare practitioners a broad portfolio of innovative gastroenterology products. "We are delighted with the growth and progress of GI Supply over the past several years. We thank Patricia Industries and Laborie for their partnership in helping to develop this business. The future is very bright for GI Supply as part of Laborie." Ashley Friedman, Managing Director at Signet Healthcare Partners Yuriy Prilutskiy, Head of North America at Patricia Industries, a part of Investor AB and majority owner of Laborie Medical Technologies added, "Patricia Industries is excited to continue investing in Laborie's long-term growth with this acquisition. We continue to support Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity." About Laborie Medical Technologies Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program. Laborie is a portfolio company of Patricia Industries. About GI Supply As a physician-founded company, we strive for deep clinical input into all that we do. GI Supply is broadening its portfolio with solutions that allow physicians to perform more-advanced procedures safely and efficiently. We help doctors do their jobs faster, safer and simpler. About Patricia Industries Patricia Industries, a part of Investor AB, invests in best-in-class companies with strong market positions, brands and corporate cultures within industries positioned for secular growth. We invest with an indefinite holding period and partner with great management teams to create value for people and society by building strong and sustainable businesses. About Investor AB Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through our board participation, industrial experience, global network and financial strength, we work continuously to support our companies to remain or become best-in-class. About Signet Healthcare Partners Signet Healthcare Partners is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 24-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $500 million and has invested in more than 55 companies.

Read More

FUTURE OF HEALTHCARE

M1 MedTech Accelerator Program Opens Applications to Early-Stage Medical Device Companies

M1 MedTech | April 05, 2022

M1 MedTech, a medical technology accelerator sponsored by Proxima Clinical Research, a contract research organization based out of the Texas Medical Center, announcedit is accepting applications for its fall cohort. M1 MedTech is looking for five to seven of the most promising early-stage medical device companies to participate in its three-month program. The program has closed its first fund and will be selecting companies over the summer for investments up to $100,000 as a combination of both cash and in-kind services. “Our program is unique in that it combines acceleration capital, company building expertise, and the regulatory and clinical services of a top CRO,” says Larry Lawson, a venture partner and investor with M1. “Access to the M1 founders’ network, both within and outside of the Texas Medical Center, sets these companies up for success. There’s no better group to build a MedTech company with, period.” “Many MedTech companies are launched by innovative first-time founders with strong scientific and medical expertise, but who have never taken a regulated product to market or built a business. After working with so many companies at various stages of this journey to market, both with Proxima CRO and with accelerators from across the country, we realized there was a gap that needed to be filled for these rising founders. They not only need regulatory and clinical assistance from experts with hundreds of success stories in this field, we found they also need assistance with design, manufacturing, business, IP, and so much more,” says Isabella Schmitt, RAC, Director of Regulatory Affairs for Proxima CRO and Principle at M1. “These rising founders need to know what they don’t know; so, we put a lot of thought into what emerging companies and rising executives really need, and from that, we built the M1 curriculum.” M1 MedTech was created to support early-stage medical device companies, offering an immersive experience that provides tangible benefits to participating companies. The program will take on a limited number of enterprises in each cohort and offer a direct approach to helping founders advance their companies and technologies. The coaching process will include a curated educational program, interactive workshops where participants can continually build out specific company deliverables, and tailored one-on-one mentoring. “This is a very personalized program for early-stage companies focused on Class II and III medical devices,” said Sean Bittner, PhD, ACC, Director of Programs at M1 MedTech. “We’re excited to welcome our first cohort this August. The medical device companies that fit best with our program are in pre-seed or seed-stage, have completed a customer evaluation, know the issues they want to address, have not progressed far enough through the pipeline to have communicated with the FDA or completed preclinical or clinical testing,” says Bittner. “We would like the companies to have completed preliminary testing but have not gone too far into the product development phase.” “This is a fantastic opportunity for an early-stage company to receive mentoring and guidance from a group of established individuals in the life sciences industry. The hands-on 12-week workshop curriculum will cover a variety of topics including company formation and management, preclinical and clinical testing, regulatory approval, among other necessary guidance as their companies begin to mature. We are excited to aid the founders in rapidly advancing toward commercialization and prepare them for critical early investment stages.” Kevin Coker, CEO at Proxima CRO and Principal at M1 MedTech Experts from Greenlight Guru, Medrio, Galen Data, and Merge Medical Device Studio join Proxima CRO as sponsors of the program and will assist with content delivery and mentoring. Applications will remain open until May 31. About M1 MedTech M1 MedTech is an accelerator/incubator designed to build MedTech companies. The program offers capital, entrepreneurial expertise, and CRO services, as well as an immersive experience offering a hands-on approach to guide founders as they become MedTech executives and advance their companies and technologies. The coaching process includes a curated educational program with a focus on regulatory and quality dynamics, one-on-one mentoring, and interactive workshops where participants can continually build out specific company deliverables.

Read More

MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

HEALTH TECHNOLOGY

Murata Vios Announces Integration with PointClickCare’s EHR Platform

Murata Vios, Inc | June 24, 2022

Murata Vios, Inc., developer of the Vios Monitoring System, is proud to announce the launch of its integration with PointClickCare, the leading cloud‐based software vendor for the senior care market. The integration will allow healthcare facilities to seamlessly integrate vital signs data into residents’ electronic health records for clinical review, helping to eliminate data entry time lags, transcription errors, and improve clinician efficiency. “Real‐time understanding of a resident’s vital signs can help prevent hospital readmissions because care teams can more quickly identify and treat the early signs of clinical deterioration. With the Vios Monitoring System and its Remote Monitoring Services, PointClickCare customers have a better way to capture this data and respond to changes in a resident’s condition. It can also free up clinical time that was previously spent on manually spot‐checking and recording vital signs every few hours.” Amit Patel, CEO of Murata Vios The Vios Monitoring System is a wireless, FDA‐cleared patient monitoring platform designed to improve resident safety and outcomes. The system delivers insights and value to post‐acute care providers by Continuously monitoring vital signs. The Vios Monitoring System measures high‐fidelity 7‐lead ECG, heart rate, oxygen levels, pulse rate, respiratory rate, and posture data. Improving 24/7/365 oversight of changes in resident conditions. With Vios Remote Monitoring Services, a team of cardiac‐trained technicians can alert the on‐site care team to any changes in a resident’s condition, enabling them to quickly respond to resident deterioration that could lead to readmission. Identifying risk of pressure injuries. The Vios Chest Sensor has a built‐in 3‐axis accelerometer that detects and displays the resident’s posture in real‐time. When turn orders are added, the system can determine when a patient is at‐risk of developing a pressure injury so the on‐site care team can address the issue. Additional information regarding the integration can be found on the PointClickCare Marketplace – an online platform that enables customers to easily evaluate authorized third-party technology partners. Partners listed on the PointClickCare Marketplace offer integrated apps and/or services that are designed to be quickly deployed and work seamlessly with providers’ existing workflows. “The PointClickCare Marketplace offers the widest range of integrated solutions available to the market,” says Chris Beekman, Marketplace Director, PointClickCare. “Our partnership with Murata Vios is further testament to our continually growing partner network and ecosystem, and the wealth of possibilities it provides our customers to extend their technology capabilities.” About Murata Vios, Inc. Murata Vios, Inc., a subsidiary of Murata Manufacturing Co., Ltd., developed the Vios Monitoring System (VMS) to improve patient outcomes and reduce costs across the care continuum. Healthcare facilities can use the wireless, FDA‐cleared vital signs monitoring solution on existing IT infrastructure and instantly deploy the VMS to meet the acuity needs of patients across various care settings. Vios Remote Monitoring Services support healthcare teams with real‐time patient event analysis and notifications, helping to maximize patient safety while minimizing the burden on stretched clinical staff. About PointClickCare PointClickCare is a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at any stage of a patient’s healthcare journey. PointClickCare’s single platform spans the care continuum, fostering proactive, holistic decision‐making and improved outcomes for all. Over 22,000 long‐term post‐acute care providers, and 1,600 hospitals use PointClickCare today, enabling care collaboration and value‐based care delivery for millions of lives across North America.

Read More

Spotlight

Compensation from a Provider to a physician in the form of
items or services (reward, award, or other gratuity) that does
not exceed the annually adjusted cap amount (see below).
Requirements include: The compensation is not determined in a manner that takes into account the volume or value of referrals or other business generated by the referring physician.

Resources